MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2212
-0.0038
-1.69%
Pre Market: 0.2202 -0.001 -0.45% 08:26 07/06 EDT
OPEN
0.2300
PREV CLOSE
0.2250
HIGH
0.2350
LOW
0.2180
VOLUME
5.27M
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
0.1700
MARKET CAP
24.38M
P/E (TTM)
0.1057
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OCGN stock price target is 0.7000 with a high estimate of 0.7000 and a low estimate of 0.7000.

EPS

OCGN News

More
Ocugen Shares Spike Following Mention Of Stock By Twitter Users
https://twitter.com/MrZackMorris/status/1275509438435209216
Benzinga · 06/23 19:27
Ocugen Stock Is a Gamble, Not an Investment Opportunity
Are you familiar with Ocugen (NASDAQ:OCGN), the penny stock that took a massive plunge in 2019? OCGN stock closed near $14 on Sept. 26. Three sessions later, it closed at $2.19.Source: Shutterstock The stock has been on a painful descent since then, most recen
InvestorPlace · 06/12 17:39
Chardan Capital Maintains Buy on Ocugen, Lowers Price Target to $0.7
Chardan Capital analyst Keay Nakae maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $2 to $0.7.
Benzinga · 06/03 16:33
Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board
GlobeNewswire · 06/03 13:30
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1)
Benzinga · 06/02 11:45
HC Wainwright & Co. Downgrades Ocugen to Neutral
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Ocugen (NASDAQ:OCGN) from Buy to Neutral.
Benzinga · 06/01 16:07
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 3 companies hit new 52-week lows.
Benzinga · 06/01 14:43
Ocugen to Discontinue Phase 3 oGVHD Trial
GlobeNewswire · 06/01 14:20

Industry

Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About OCGN

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).
More

Webull offers kinds of Ocugen Inc stock information, including NASDAQ:OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.